Floatz logo

Sorafenib

Portal Vein Tumor Thrombus

First Affiliated Hospital of Zhejiang UniversitySmall moleculePhase 4 / ApprovedDormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Portal Vein Tumor Thrombus cohort.

Asset / SponsorPhaseRating
LENVATINIB
First Hospital of China Medical University
Phase 4BBB
WARFARIN
Kafrelsheikh University
Phase 4BB
NADROPARIN
Shanghai Zhongshan Hospital
Phase 4BB
Enoxaparin
Institute of Liver and Biliary Sciences, India
Phase 4BB
CARVEDILOL
Asian Institute Of Medical Sciences
Phase 4B

View all 27 →

Same molecule, other indications

Sorafenib is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
79 / 100
View asset →
SorafenibDormant
BBB
Indicative ·
75 / 100
View asset →
hepatocellular carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →